{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:59:06Z","timestamp":1773212346631,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T00:00:00Z","timestamp":1486944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/1\u2010093\u201001\/503\u201011\u2010003"],"award-info":[{"award-number":["503\/1\u2010093\u201001\/503\u201011\u2010003"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intensive induction chemotherapy using anthracycline and cytarabine backbone is considered the most effective upfront therapy in physically fit older patients with acute myeloid leukemia (AML). However, outcomes of the standard induction in elderly AML are inferior to those observed in younger patients, and they are still unsatisfactory. As addition of cladribine to the standard induction therapy is known to improve outcome in younger AML patients. The present randomized phase II study compares efficacy and toxicity of the DAC (daunorubicin plus cytarabine plus cladribine) regimen with the standard DA (daunorubicin plus cytarabine) regimen in the newly diagnosed AML patients over 60 years of age. A total of 171 patients were enrolled in the study (DA, 86; DAC, 85). A trend toward higher complete remission (CR) was observed in the DAC arm compared to the DA arm (44% vs. 34%; <jats:italic>P<\/jats:italic>\u2009=\u2009.19), which did not lead to improved median overall survival, which in the case of the DAC group was 8.6 months compared to in 9.1 months in the DA group (<jats:italic>P<\/jats:italic>\u2009=\u2009.64). However, DAC appeared to be superior in the group of patients aged 60\u201065 (CR rate: DAC 51% vs. DA 29%; <jats:italic>P<\/jats:italic>\u2009=\u2009.02). What is more, a subgroup of patients, with good and intermediate karyotypes, benefited from addition of cladribine also in terms of overall survival (<jats:italic>P<\/jats:italic>\u2009=\u2009.02). No differences in hematological and nonhematological toxicity between the DA and DAC regimens were observed.<\/jats:p>","DOI":"10.1002\/ajh.24654","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T05:37:35Z","timestamp":1484890655000},"page":"359-366","source":"Crossref","is-referenced-by-count":25,"title":["Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial"],"prefix":"10.1002","volume":"92","author":[{"given":"Agnieszka","family":"Pluta","sequence":"first","affiliation":[{"name":"Department of Hematology Medical University of Lodz Lodz Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical University of Lodz Lodz Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Wrzesien\u2010Kus","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical University of Lodz Lodz Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozena","family":"Katarzyna Budziszewska","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimierz","family":"Sulek","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology Military Medical Academy Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Wawrzyniak","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical University of Lodz Lodz Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Czemerska","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical University of Lodz Lodz Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Zwolinska","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical University of Lodz Lodz Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Golos","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical University of Lodz Lodz Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Holowiecka\u2010Goral","sequence":"additional","affiliation":[{"name":"Department of Oncology Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slawomira","family":"Kyrcz\u2010Krzemien","sequence":"additional","affiliation":[{"name":"University Department of Hematology and BMT Silesian Medical University Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Piszcz","sequence":"additional","affiliation":[{"name":"Department of Hematology Bialystok Medical Academy Bialystok Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Kloczko","sequence":"additional","affiliation":[{"name":"Department of Hematology Bialystok Medical Academy Bialystok Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Mordak\u2010Domagala","sequence":"additional","affiliation":[{"name":"L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, Poland and Lower Silesian Center for Cellular Transplantation &amp; National Bone Marrow Donor Registry Wroc\u0142aw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Lange","sequence":"additional","affiliation":[{"name":"L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, Poland and Lower Silesian Center for Cellular Transplantation &amp; National Bone Marrow Donor Registry Wroc\u0142aw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Razny","sequence":"additional","affiliation":[{"name":"Hematology Department Rydygier Memorial Hospital Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Madry","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Internal Diseases Medical University of Warsaw Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wieslaw","family":"Wiktor\u2010Jedrzejczak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Internal Diseases Medical University of Warsaw Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention, Faculty of Public Health Silesian Medical University Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Butrym","sequence":"additional","affiliation":[{"name":"Department of Physiology Wroclaw Medical University Wroclaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimierz","family":"Kuliczkowski","sequence":"additional","affiliation":[{"name":"Department of Hematology and Proliferative Diseases Wroclaw Medical Academy Wroclaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Warzocha","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Holowiecki","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation Comprehensive Cancer Center, M. Sklodowska\u2010Curie Memorial Institute Gliwice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation Comprehensive Cancer Center, M. Sklodowska\u2010Curie Memorial Institute Gliwice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Szydlo","sequence":"additional","affiliation":[{"name":"Hammersmith Hospital Centre for Haematology, Imperial College London London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-457X","authenticated-orcid":false,"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical University of Lodz Lodz Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-379008"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435669"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623447"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-551499"},{"key":"e_1_2_7_7_1","first-page":"110","article-title":"National Comprehensive Cancer Network (NCCN) guidelines for acute myeloid leukemia, version 1","author":"O'Donnell MR","year":"2016","journal-title":"J Natl Compr Cancer Netw."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403336"},{"key":"e_1_2_7_9_1","first-page":"518","article-title":"No additional toxicity from cladribine (CdA) when given with cytosin arabinoside and idarubicin (CCI) as primary treatment of acute myeloid leukemia in elderly patients: Results from a randomized phase II\u2010study from the leukemia group of middle Sweden (LGMS)","volume":"98","author":"Juliusson G","year":"2001","journal-title":"Blood."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00988.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1046-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_7_13_1","first-page":"1","volume-title":"An International System for human Cytogenetic Nomenclature","author":"Shaffer LG","year":"2009"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21723"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-182782"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1286"},{"key":"e_1_2_7_18_1","article-title":"Phase II study of cladribine, idarubicin, and cytarabine (araC) in patients with acute myeloid leukemia (AML)","author":"Kadia T","year":"2015","journal-title":"Blood."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270330"},{"key":"e_1_2_7_20_1","first-page":"1","article-title":"Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype\u2014retrospective analysis of Polish Adult Leukemia Group (PALG)","volume":"26","author":"Wierzbowska A","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/asheducation-2014.1.14","article-title":"Treating acute myeloid leukemia in older adults","volume":"2014","author":"Wang ES.","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901409"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-069666"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.2652"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.3130"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.9743"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23544"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:26:11Z","timestamp":1695561971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,13]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1002\/ajh.24654"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24654","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,13]]}}}